CINCINNATI -- A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex (TSC) – a genetic disease characterized by benign tumors on multiple organ systems. TSC is estimated to affect more than a million individuals throughout the world.
The study is the latest to demonstrate the effectiveness of everolimus for TSC patients. Previous studies conducted at Cincinnati Children’s Hospital Medical Center showed that everolimus reduced tumors in the brain and the kidney.
The newest study, led by a physician-scientist at Cincinnati Children’s in collaboration with a team at Texas Children’s Hospital in Houston, has been accepted by the journal Annals of Neurology, and is available online.
"Everolimus treatment reduced seizure frequency and duration in the majority of TSC epilepsy patients whose seizures previously did not respond to treatment,” says Darcy Krueger, MD, PhD, a pediatric neurologist at Cincinnati Children’s, assistant professor of pediatrics at the University of Cincinnati College of Medicine and lead author of the study. "This improvement in seizure control was associated with a better quality of life, and side effects were limited. Work is already underway to confirm these results in a follow-up, phase III clinical study.”
"This has been positively life-changing for the patients involved and is nothing short of transformative in the treatment of epilepsy associated with cellular growth disorders, such as TSC,” says Angus Wilfong, MD, director of the comprehensive epilepsy program at Texas Children’s Hospital and associate professor of pediatrics and neurology at Baylor College of Medicine.
The study included 20 patients who were treated with everolimus. Their median age was 8. Half of the patients were enrolled at Cincinnati Children’s and half at Texas Children’s Hospital in Houston.
The researchers found that everolimus reduced seizure frequency by at least 50 percent in 12 of the 20 participants. The drug also reduced seizures in 17 of the 20 TSC patients by a median rate of 73 percent. Four patients were free of seizures and seven had at least a 90 percent reduction in seizure frequency.
Overall quality of life, as reported by the participants’ parents, also improved. Parents reported several positive changes, including attention, behavior, social interaction and physical restrictions.
Studies in the 1990s traced the cause of TSC to defects in two genes, TSC1 and TSC2. When these genes malfunction, the cell has higher activity of mTOR, a protein known to trigger uncontrolled tumor cell and blood vessel growth. Everolimus shrinks tumors by inhibiting mTORC1, and it appears to reduce seizures in TSC patients in the same way.
"It is unclear whether the benefit of everolimus in treating epilepsy might extend beyond that observed in TSC,” says Krueger. "mTORC1 has been implicated in genetic and neurodevelopmental syndromes in which epilepsy is prominent and in more common types of epilepsy. Additional clinical trials might tell us whether everolimus would benefit patients with epilepsy not related to TSC.”
Funding for the study was provided by Novartis Pharmaceuticals and the Clack Foundation.